Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\>90% in the

Trial Details

NCT ID
NCT06563245
Phase
PHASE2 / PHASE3
Sponsor
Children's Cancer Group, China
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Brentuximab Vedotin for Injection
  • response-adapted radiation
  • Doxorubicin
  • Etoposide
  • Prednisone
  • Cyclophosphamide
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Ages \>=2\~\<35 years at the time of enrollment;
  • Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;
  • Adequate organ function;
  • Patients and/or their parents or legal guardians sign a written informed consent;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →